News From SDEE Members

Or sign in with email

    Please check your e-mail for a link to activate your account.

    Looking for a Co-Founder!

    Hello there! Solo technical founder here. I am a former engineer, former local government sustainability planner piloting a community-scale organics waste management solution. My proof-of-concept facility has been successful so far and we're coming out of the R&D phase to lots of different entities interested in partnering.  I am in...
    Read more

    Sublease

    Sublease is available in Sorrento Mesa at <<market rate: fully furnished ~1100 sqft with executive office, large common office area and large room suitable for experimental work and storage; kitchen access optional. Please send inquiries to Reiko Bachand at [email protected]
    Read more

    Get the Newsletter

    Erythropoietic Protoporphyria: A Rare Inherited Disorder

    In this post, I share a few thoughts about erythropoietic protoporphyria (EPP), a serious debilitating condition for which there are presently no approved treatments. EPP is a rare inherited disorder of heme biosynthesis characterized by dermal photosensitivity secondary to a partial deficiency of ferrochelatase. In a phenotypically similar X-linked protoporphyria (XLP),...
    Read more

    Neuropore achieves $5 million (USD) milestone from UCB collaboration

    Neuropore announced advancement of UCB0599 to next phase.  UCB0599 is an orally bioavailable, brain barrier penetrant small molecule that prevents the oligomerization of alpha-synuclein. Alpha-synuclein oligomerization and aggregation is implicated in Parkinson’s disease and other degenerative diseases. By inhibiting misfolding and oligomerization of alpha-synuclein, it is believed that the progression...
    Read more

    Neuropore introduces a 2nd drug into the clinic. Has an eye for Parkinson's disease and ALS.

    Neuropore Therapies announced that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of NPT520-34. NPT520-34 is an orally bioavailable, blood-brain barrier penetrating small molecule. Its mode of action is attenuation of neuroinflammation...
    Read more

    Pharmaceutical & Medical Device Regulatory Affairs Director

    Collidion, Inc. and it’s subsidiaries,  Plex Pharmaceuticals & Avenlogics, Inc has an immediate full-time position open for Pharmaceutical & Medical Device Regulatory Affairs Director. Position: Full-time Location: Flexible To apply, visit www.collidion.com/careers   Founded in 2015, Collidion, Inc. is a private healthcare company with two subsidiaries, Avenlogics, Inc. and Plex...
    Read more

    Become a Member

    Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

    Learn More